Combinatorial nanomedicines for precision therapy of prostate cancer at the IOR – New grant awarded to Prof. Carlo Catapano

New grant awarded to the Tumor Biology and Experimental Therapeutics Group headed by the IOR Director Prof. Carlo Catapano (http://www.ior.usi.ch). The project Nanoparticle-based delivery and combinatorial therapies for cancer funded by SNSF in the context of the European COST action on Cancer Nanomedicine (CA17140) aims at developing new nanoparticle-based medicine for precision therapy of adv...
More

Full professorship at ETH Zurich granted to Prof. Dr. Andrea Alimonti

Professor Andrea Alimonti, MD, group leader at the Institute of Oncology Research (IOR, affiliated with USI) and Full professor at the USI Faculty of Biomedical Sciences, has been appointed by the ETH Board as Full professor of Experimental oncology and translational cancer medicine at the ETH Zurich. https://www.usi.ch/en/feeds/12525 https://ethz.ch/en/news-and-events/eth-news/news/2019/12/...
More

Robert Wenner Prize to Andrea Alimonti

The Swiss Cancer League has awarded this year's Robert Wenner Prize for young cancer researchers to Andrea Alimonti. With his work, the researcher and doctor has discovered how cancer cells age - and how this so-called senescence can be used therapeutically. More information on the Robert Wenner Prize
More

Prostate cancer, accolades for two IOR researchers

A research project on prostate cancer conducted at the Institute of Oncology Research (IOR, affiliated to USI), won a PCF Challenge Award 2019 worth $1 million at the annual conference of the PCF Prostate Cancer Foundation, the leading U.S. agency in the field, on October 25 in Carlsbad, California. The study of the international research team, led by Prof. Andrea Alimonti, group leader at the IOR...
More

IOR receives important funding from SNSF to advance its prostate cancer research efforts

Dr. Giuseppina M. Carbone, Prostate Cancer Biology Group, receives a 4-year grant of 700’000 CHF from Swiss National Science Foundation (SNSF) to study a transcription factor that acts as tumor suppressor to prevent development of aggressive prostate tumors in men. Dr. Carbone has a longstanding record of accomplishment in investigating the role of ETS transcription factors in prostate cancer. ...
More